Production and differential activity of recombinant human wild-type G6PD and G6PDViangchan
Categoría del artículo: Technical report
Publicado en línea: 20 sept 2020
Páginas: 159 - 167
DOI: https://doi.org/10.1515/abm-2020-0023
Palabras clave
© 2020 Lelamekala Vengidasan et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Human
G6PD deficiency is the most common genetic enzyme deficiency with a prevalence of approximately 400 million people worldwide [6, 7]. To date, there is no cure for G6PD deficiency, and it is a chronic lifelong condition. Treatment is often focused on managing the hemolysis or lifelong blood transfusion. Although mortality resulting from G6PD deficiency is very low or rare, in severe cases, the deficiency can lead to kidney failure or death. G6PD deficiency has also been linked to various types of cancers, tumors, and metabolic diseases and patients often experience low quality of life.
G6PD deficiency was first found in African Americans and thought to be restricted to one ethnic group. Subsequently, it was found that G6PD deficiency is an X-linked genetic disorder that is more common in men and boys than women and girls. In 1961, it became evident that the disorder was not exclusive to people with African ancestry, but also affects people with Southern European and the Middle Eastern ancestry. In 1967, the World Health Organization (WHO) published a standard method to measure the G6PD enzyme activity [8] and later, in 1971, the G6PD deficiency variants classification according to the severity of the phenotypes was published. By 1988, more than 370 variants had been described [9]. Currently, more than 500 variants are described. The prevalence of G6PD deficiency in Malaysia is around 3.1% in the male population and is most common among Malays and Malaysian Chinese, and less common among those with Indian ancestry [10, 11]. A small study comprising 87 people resulted in similar findings, but with a higher prevalence of 4.59% [12]. The most common types of variants in the Malay ethnic group are G6PDViangchan (37.2%), followed by G6PDMediterranean (26.7%), and G6PDMahidol (15.1%) [13, 14]. The G6PDViangchan variant carries a point mutation at position 871 (G>A) [15].
In humans, the Viangchan-type variant can reduce G6PD expression by up to 80%–90%, which is based on biochemical characterization of enzyme partially purified from the RBC of those with the Viangchan-type variant [15] and this severe deficiency is classified as a WHO G6PD Class II variant [16], with <10% of wild-type G6PD activity, and has clinical implications, such as intermittent hemolysis.
A number of different G6PD deficient variants have been produced in heterologous expression systems, such as G6PDYucatan, G6PDNashville, G6PDValladolid and G6PDMexico City [17], G6PDVolendam [18], G6PDPlymouth and G6PDMahidol [19], G6PDWisconsin [20, 21], G6PDFukaya and G6PDCampinas [21], G6PDViangchan [22, 23], and G6PDZacatecas and G6PDVanua-Lava [23]. Although G6PDViangchan has previously been cloned, produced, and characterized previously [22, 23], different template source/vectors, expression systems, methods, conditions, and parameters were used in each study, indicating the diversity of techniques that can be used to study the gene and enzyme. Previously, direct comparisons have been made between different recombinant human G6PD, such as between G6PDViangchan and G6PDViangchan + Mahidol [22], G6PDZacatecas, G6PDVanua-Lava, and G6PDViangchan [23], and between wild-type G6PD and 5 other G6PD variants (excluding Viangchan) [24].
In the present study, we aimed to clone, produce, and compare protein production and enzyme activity of both the wild-type G6PD and the G6PDViangchan variant in parallel, to establish a simple, efficient, and optimized method to produce the G6PD variant. Such a protocol may be useful to create a model system to study G6PD deficiency disease.
The PCR product and pET26b(+) (Novagen) were digested using

Agarose gel electrophoresis showing purified 5.9 kb vector pET26b (lane V), the PCR-amplified glucose-6-phosphate dehydrogenase gene (
The mutation was initiated in wild-type
Genes for wild-type G6PD and G6PDViangchan were transformed into
Proteins (30 μg) were loaded into wells in a 5% polyacryl-amide stacking gel on top of a 12.5% polyacrylamide resolving gel (8.3 cm × 7.3 cm) and separated for 90 min at 180 V in 1 × running buffer (Tris-glycine buffer with 10% SDS) using a Mini-Protean Tetra cell system (Bio-Rad). The proteins in the gel were stained with Coomassie Blue R-250 staining solution for about 30 min and destained using distilled water.
For western blotting analysis, the protein in an unstained gel was transferred to a polyvinylidene difluoride (PVDF) membrane in a semidry manner using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (catalog No. 170-3940; Bio-Rad) in transfer buffer (containing 25 mM Tris, 192 mM glycine, 20% (v/v) methanol (pH 8.3)) at 18 V for 1 h. Non-specific binding to the membrane was then blocked with 5% skimmed milk in phosphate buffered saline (PBS) for 1 h at room temperature. Subsequently, the membrane was incubated with polyclonal rabbit anti-G6PD (1:1,000 dilution; Cell Signaling Technologies, catalog No. 8866S), polyclonal rabbit anti-6′HisTag (1:1,000 dilution; Abcam, catalog No. ab14923) and polyclonal rabbit anti-β-actin (1:1,000 dilution; Abcam, catalog No. ab8227) primary antibodies, overnight at 4 °C. The primary antibodies were diluted in PBS with 5% skimmed milk and 0.1% Tween-20. After washing several times in PBS, the membrane was incubated with goat anti-rabbit IgG (H and L) secondary antibody conjugated to horseradish peroxidase (HRP) (1:10,000 dilution; Abcam catalog No. ab6721). β-Actin protein served as a loading control to show that equal amounts of protein was loaded into the wells. Benchmark Pre-Stained Protein Ladder (Invitrogen, catalog No. 10748010) was used to provide size markers. Finally, enhanced chemiluminescence (ECL) Western Blotting Detection Reagents (GE Healthcare) were used to detect the protein bands and the image was viewed and documented using a Versadoc Imaging system (Bio-Rad).
G6PD was purified using a HisTALON Gravity Column Purification kit (TaKaRa Clontech). As a starting material, we used 10 g of cell pellet. The pellet was suspended in 5 mL of lysis buffer and incubated on ice for 15 min. The suspension was sonicated on ice with 10 short pulses (10 s) followed by pauses (30 s) and was centrifuged at 10,000 ×
The wild-type G6PD structure (PDBID: 2HB9) was retrieved from the RCSB Protein Data Bank was subjected to point mutation in silico using the UCSF Chimera Rotamer tool [25]. Valine 291 was changed to methionine (V291M; G6PDViangchan). The side chain rotamer of the mutated residue was selected based on the Dynameomics rotamers library [26].
The G6PDViangchan variant was subjected to energy minimization in silico to optimize the initial geometry of the protein structure by removing possible steric clashes. The energy minimization was performed using the Gromacs simulation package (version 4.6.7) [27].
To understand the impact of mutation on the molecular interaction between G6PDViangchan and the structural NADP+, flexible small molecule and rigid protein docking was performed using AutoDock (version 4.2) [28]. Initially, the wild-type G6PD PDB file was cleaned by removing the existing NADP+ coordinate lines to create an “apoform” wild-type G6PD protein PDB file to be docked with the NADP+ structure using docking. The nonpolar hydrogen atoms were merged and total Kollman and Gasteiger charge were added to the protein. We ensured that there were no nonbonded atoms in the protein. Kollman and Gasteiger partial charges were also assigned to the NADP+ and all torsions were allowed to rotate during docking. Residues of the structural NADP+ binding site were specified based on the details obtained from previous work [29]. A grid box was assigned around the selected active site to cover the entire protein with a dimension of 60 × 60 × 60. The Lamarckian Genetic Algorithm (LGA) option was set to 150 runs with default parameter settings. The best conformation with the lowest docking energy was selected from the docking search. The interaction of structural NADP+ and wild-type G6PD including hydrogen bonds and hydrophobic interaction was analyzed using LigPlot+ (version 2.1) [30]. The same docking simulation approach was used for G6PDViangchan.
Mammalian Gene Collection (MGC) clones are commercially available sequence-validated full-length protein-coding cDNA clones for human, mouse, and rat from Dharmacon (GE Healthcare). pOTB7, which was used as the PCR template, contains human G6PD cDNA (GenBank RNA accession No. NM_001042351.2). The full-length of the gene contains 2295 bp nucleotides that include 128 bp upstream of

Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) of unpurified and purified glucose-6-phosphate dehydrogenase (G6PD). After electrophoresis, the proteins in the 12.5% polyacrylamide resolving gel were stained with Coomassie Blue R. The purified G6PD has a molecular mass of 59 kDa. Lane 1: Benchmark Pre-Stained Protein Ladder (Invitrogen, catalog No. 10748010). Lane 2: unpurified wild-type protein. Lane 3: purified wild-type protein. Lane 4: unpurified Viangchan variant protein. Lane 5: purified Viangchan variant protein).

Western blot analysis of lysates containing unpurified and purified glucose-6-phosphate dehydrogenase (G6PD) protein using anti-G6PD (upper panel), anti-6 × HisTag (lower panel) and anti-β-actin antibodies (both panels). A distinct single band is visible indicating immunoreactivity of target proteins to anti-G6PD, and anti-6 × His-Tag antibodies. No band is visible when purified G6PD protein was incubated with anti-β-actin antibody indicating the G6PD protein was purified successfully. Lane M: Benchmark Pre-Stained Protein Ladder (Invitrogen, catalog No. 10748010; markers shown are 82, 64, 49, 37 kDa). Lane 1: unpurified wild-type enzyme. Lane 2: purified wild-type enzyme. Lane 3: unpurified Viangchan variant. Lane 4: purified Viangchan variant).
The genomic sequence variation from G>A results in an amino acid substitution of valine by methionine and the protein variation exists at amino acid position 291. The residue is located at alpha helix loop 11 and is highly exposed to solvent. The alpha strand is connected to the Rossmann fold, which is characterized by an alternating motif of β-strand-α-helix-β-strand secondary structures. The initial β-α-β fold is the most conserved segment of the Rossman fold, and is responsible for FAD, NAD+, and NADP+ binding [31, 32]. It is assumed that the mutation might disrupt the orientation of the fold indirectly. A simple docking by using AutoDock revealed that the variant residues do not alter the NADP+ ligand binding site or the G6PD directly, but is located nearby. The binding energy obtained for NADP+ toward wild-type G6PD was –7.7 kJ/mol and that for G6PDViangchan was –7.6 kJ/mol. The NADP+ ligand is located at the center of the Rossman fold (

Three-dimensional structure of glucose-6-phosphate dehydrogenase (G6PD)Viangchan obtained through mutation in silico. The wild-type G6PD structure (PDBID: 2HB9) was retrieved from the RCSB Protein Data Bank and subjected to mutation in silico using the UCSF Chimera Rotamer tool [25]. Valine 291 was changed to methionine (in red) (G6PDViangchan). The side chain rotamer of the mutated residue was selected based on the Dynameomics rotamers library [26]. The energy minimization was performed on the G6PDViangchan variant (V291M) using the Gromacs simulation package (version 4.6.7) [27]. The molecular docking was performed using AutoDock (version 4.2) [28]. The yellow region represents the structural nicotinamide adenine dinucleotide phosphate (NADP+) binding site and green region represents substrate binding site.
Here, we report successful cloning of the full-length of
Specific enzyme activity (U/mg) of heterologous glucose-6-phosphate dehydrogenase
Wild-type G6PD | 210 | 180 | 182 | 210 | 224 | 224 | 230 | 228 |
Amsterdam | – | – | – | 95 | – | – | – | – |
Volendam | 36 | – | – | – | – | – | – | – |
Wisconsin | – | – | – | – | 178 | – | – | – |
Nashville | – | 130 | – | – | – | 103 | – | – |
Yucatan | – | – | – | – | – | 132 | – | – |
Valladolid | – | – | – | – | – | 92 | – | – |
Mexico City | – | – | – | – | – | 175 | – | – |
Mahidol | – | – | 177 | – | – | – | – | 141 |
Fukaya | – | 175 | – | – | – | – | – | – |
Champinas | – | 160 | – | – | – | – | – | – |
Plymouth | – | – | 187 | – | – | – | – | – |
Viangchan | – | – | – | – | – | – | 228 | 107 |
Zacatecas | – | – | – | – | – | – | 58 | – |
Vanua-Lava | – | – | – | – | – | – | 182 | – |
G6PD, glucose-6-phosphate dehydrogenase.
The V291M variant residue of G6PDViangchan is located some distance from the structural binding site of NADP and the substrate (
We successfully cloned, expressed, and purified both wild-type G6PD and G6PDViangchan proteins. Although the reduction in G6PD activity obtained in the variant was lower than expected, the specific enzyme activity of the recombinant protein obtained was consistent with the activity achieved by others. Such a protocol may be useful for creating a model system to study G6PD deficiency disease, which would be useful for future understanding of the molecular mechanisms underlying the observed clinical phenotypes, and could be valuable in the quest to develop new therapies for this disease.